Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Yuan Xianglin,Zhang Mingsheng,Hou Huiying.Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41:150-150.
APA：
Yuan, Xianglin,Zhang, Mingsheng&Hou, Huiying.(2023).Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial.JOURNAL OF CLINICAL ONCOLOGY,41,
MLA：
Yuan, Xianglin,et al."Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial".JOURNAL OF CLINICAL ONCOLOGY 41.(2023):150-150
医学